The Lipo-MERIT trial is the first in-human testing an mRNA vaccine (BNT111/Melanoma FixVac), a liposomal formulation of mRNA encoded against four distinct malignant melanoma-associated antigens: NY-ESO-1, melanoma-associated antigen A3, tyrosinase, and transmembrane phosphatase with tensin homology (ClinicalTrials.gov Identifier: NCT02410733). This evidence concerns the gene TPTE and melanoma.